Actively Enrolling Clinical Studies for Alzheimer’s and Dementia at The CRCNJ

To find out if you’re eligible, contact us at 973 850 4622 or click on the link to the trial of interest, complete the online form, and we will contact you.

Actively Enrolling Clinical Trials

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD) (Graduate Study)

Sponsor: Hoffman-La Roche

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. (Click here: https://clinicaltrials.gov/ct2/show/NCT03443973?term=gantenerumab&cond=Alzheimer+Disease&rank=1)

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer’s Disease

Sponsor: Eli Lilly

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer’s Disease (AD). (Click here: https://clinicaltrials.gov/ct2/show/NCT03518073?term=lmdc&cond=Alzheimer+Disease&rank=1)

A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer’s Disease (MissionAD1)

Sponsor: Eisai Co., Ltd.

The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer’s Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of elenbecestat.

Phase 2 Study of BIIB092 in Participants With Early Alzheimer’s Disease (TANGO)

Sponsor: Biogen

To evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or with mild AD. To evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in participants with MCI due to AD or with mild AD. To evaluate the immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with mild AD.

A Study of Bryostatin in Moderately Severe to Severe Alzheimer’s Disease Subjects Not On Memantine (Neurotrope)

Sponsor: Neurotrope Bioscience, Inc.

This is a randomized double-blind Placebo-controlled, Phase 2 study comparing bryostatin to placebo for the treatment of moderately severe to severe Alzheimer’s disease in subjects not receiving memantine treatment.

A Study of LY3154207 in Participants With Parkinson’s Disease Dementia (PRESENCE)

Sponsor: Eli Lilly

A randomized placebo-controlled trial in individuals with Parkinson’s disease dementia to evaluate the safety and efficacy of three doses of study drug LY3154207 in participants with mild-to-moderate Parkinson’s disease dementia treated for 12 weeks.

Closed to Recruitment

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer’s Disease (CREAD study)

Sponsor: Hoffmann-La Roche
Closed to enrollment

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The final efficacy and safety assessment will be performed 52 weeks after the last crenezumab dose.

A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer’s Disease or Vascular Dementia

Sponsor: Charsire Biotechnology Corp
Closed to enrollment

A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient with Alzheimer’s Disease or Vascular Dementia

CREAD Study A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer’s Disease (AD)

Sponsor: Hoffmann-La Roche.
Closed to enrollment

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The final efficacy and safety assessment will be performed 52 weeks after the last crenezumab dose.

Click here to read the full study at clinicaltrials.gov.

Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study

Sponsor: American College of Radiology Imaging Network
Closed to enrollment

The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study will establish an open-label, longitudinal cohort study to assess the impact of amyloid PET on patient outcomes. Our hypothesis is that amyloid PET will decrease uncertainty and increase confidence in the underlying cause of cognitive impairment, that this will translate into earlier counseling and interventions in these domains, and that these interventions will lead to improved outcomes.clinicaltrials.gov.

Registry of Amyloid Positive Patients for Alzheimer’s Disease Drug Research Trials (RAmP Registry)

Sponsor: Eli Lilly & Co.
Closed to enrollment

This registry will be used to identify patients who have etiology diagnosed or suspected to be Alzheimer’s disease and positive amyloid scans, and have indicated their interest in being contacted for an Eli Lilly and Company (Lilly) Alzheimer’s Disease drug research trial.clinicaltrials.gov.

A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer’s Disease Currently Recruiting (AMARANTH)

Sponsor: Eli Lilly & Company and AstraZeneca
Closed to enrollment

The purpose of this study is to assess the efficacy and safety of lanabecestat compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. clinicaltrials.gov.

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer‘s Disease (Prodromal Alzheimer’s Disease) and Mild to Moderate Dementia Due to Alzheimer’s Disease

Closed to enrollment

Sponsor: Eisai Inc.

This is a Phase 2 study to evaluate safety and efficacy in participants with Mild Cognitive Impairment due to Alzheimer’s Disease/Prodromal Alzheimer’s Disease (referred to as MCI/Prodromal) and mild to moderate dementia due to Alzheimer’s Disease (referred to as mild to moderate AD). clinicaltrials.gov.

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease

Closed to enrollment

Sponsor: Neurotrope Bioscience, Inc.

This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer’s disease. The study is 28 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose of study drug. clinicaltrials.gov.

Open-Label Study of TRx0237 in Subjects With Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Closed to enrollment

Sponsor: TauRx Therapeutics Ltd

The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial with TRx0237 continued access to therapy and to evaluate the long-term safety of TRx0237.  clinicaltrials.gov.

The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer’s Disease.

Closed to enrollment

Sponsor: TauRx Therapeutics Ltd

The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer’s Disease. clinicaltrials.gov.